^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET-targeted antibody-drug conjugate

    Related drugs:
    1d
    A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    16d
    Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer. (PubMed, Acta Oncol)
    These data suggest that c-Met protein OE is associated with MET mRNA expression, shows limited overlap with other MET aberrations, and may be linked to poor prognosis in NSCLC.
    Retrospective data • Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    PD-L1 expression • MET amplification • MET overexpression • MET expression
    |
    Emrelis (telisotuzumab vedotin-tllv)
    29d
    LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=270, Active, not recruiting, AbbVie | Trial primary completion date: Oct 2025 --> Jul 2026
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR wild-type • MET overexpression • MET expression
    |
    Emrelis (telisotuzumab vedotin-tllv)
    1m
    Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer (clinicaltrials.gov)
    P1, N=30, Terminated, Regeneron Pharmaceuticals | Phase classification: P1/2 --> P1 | Trial completion date: Oct 2027 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Oct 2025; Sponsor decision
    Phase classification • Trial completion date • Trial termination • Trial primary completion date
    |
    MET overexpression
    |
    Libtayo (cemiplimab-rwlc) • REGN5093-M114
    1m
    HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safety Profiles. (PubMed, Mol Cancer Ther)
    In summary, HRA00129-C004 is a superior c-Met ADC with relatively low affinity to c-Met, efficient internalization, and strong bystander effect. It is currently being investigated in a Phase I clinical trial for patients with advanced solid tumors.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    HRA00129-C004
    1m
    First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=310, Recruiting, VelaVigo Bio Inc | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    2ms
    A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan (clinicaltrials.gov)
    P2, N=125, Not yet recruiting, AbbVie
    New P2 trial • Adverse events
    |
    telisotuzumab adizutecan (ABBV-400)
    2ms
    A Study of MHB042C in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P1/2 trial
    3ms
    A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Not yet recruiting, BeiGene
    New P1 trial • First-in-human
    3ms
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=430, Not yet recruiting, AbbVie
    New P2/3 trial • Adverse events
    |
    telisotuzumab adizutecan (ABBV-400)
    3ms
    LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=270, Active, not recruiting, AbbVie | Trial primary completion date: Jul 2026 --> Oct 2025
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR wild-type • MET overexpression • MET expression
    |
    Emrelis (telisotuzumab vedotin-tllv)
    3ms
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=694, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    Tagrisso (osimertinib) • telisotuzumab adizutecan (ABBV-400)